Research summary
In precision cancer medicine, each patient’s treatment includes the drugs that are most likely to benefit them as an individual. Not only does this lead to better outcomes-it also spares patients the costs and side effects of drugs that may not work as well for them. Dr. Thomas Kislinger, Canada Research Chair in Cancer Precision Medicine, is working to advance our knowledge in this area.
A world leader in clinical proteomics and the discovery of cancer biomarkers and drug targets for multiple cancers, Kislinger is building on his previous work to discover liquid biopsy biomarkers for aggressive prostate cancer. He and his research team are also identifying new cell surface antigens for immunotherapy and examining the cellular heterogeneity of mammary cells by developing a new, ultra-low input proteomics approach. Their work is advancing Canada’s position as a leader in precision cancer medicine.